NY-PYRAMID-ANALYTICS
5.10.2022 21:05:35 CEST | Business Wire | Press release
Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, today announced a new business practice dedicated to the specific needs of U.S. federal agencies. Led by a team of experts with a deep background in the federal market segment, Pyramid’s Federal Business Practice builds on the company’s success with federal agencies such as the U.S. Department of Veterans Affairs (VA) and strengthens its focus and commitment to providing the U.S. Federal Government and federal partners with sales, technical expertise, and services to deploy Decision Intelligence for strategic uses at scale.
Key Points:
- Decision Intelligence enabled by AI and Machine Learning (ML) can modernize the delivery of critical public services, including healthcare, homeland security, and defense in the US federal market segment.
- President Biden’s Fiscal Year (FY) 2023 Budget proposes spending $65 billion on IT for civilian federal agencies and prioritizes IT Modernization, Cybersecurity, and Digital Customer Experience initiatives that leverage advanced analyticsi.
- The Pyramid Decision Intelligence Platform, training, and consulting services will be provided directly and through partnerships with federal resellers and federal system integrators.
- The Pyramid Platform can be deployed on any cloud platform on-premises or in hybrid and multi-cloud environments
Pyramid’s US Federal Practice is led by Joe Fritsch, Director of Federal Sales; Peter Morris, Senior Director Partner Channel, North America; Dave Henry, Senior Vice President, Strategic Alliances; Russ Cosentino, Regional Vice President Sales, North America, East; and Brian McCormac, Senior Vice President of Global Sales.
The Pyramid Decision Intelligence Platform can be deployed on any cloud platform, including AWS, Google Cloud Platform and Microsoft Azure, on-premises or in hybrid and multi-cloud environments. The Pyramid Platform is available in the AWS Marketplace and can be run on AWS GovCloud to address specific regulatory and compliance requirements of agencies at the federal, state, and local level, ensuring a reliable, scalable and secure decision intelligence solution.
Decision Intelligence is Key to Government Digital Public Services
President Biden’s Fiscal Year (FY) 2023 Budget proposes spending $65 billion on IT for civilian federal agencies — an 11 percent increase from the estimate reported for 2022 — aiming to prioritize federal-wide initiatives around IT Modernization, Cybersecurity, and Digital Customer Experience. These initiatives require decisions to be made quickly, accurately and in context of outcomes and processes. Decision Intelligence enabled by AI and machine learning helps federal agencies unlock value from their data. It empowers internal decision-makers to make faster, better decisions, giving organizations the ability to generate insights, analyze data and understand roadblocks in workflows to solve problems faster and create better processes.
The use of AI and data for real-time decision making by federal civilian and defense agencies is poised to increase. Gartner estimates that by 2024, 60 percent of government AI and data analytics investments will directly impact real-time operational decisions and outcomes. The ability to identify, prioritize, model and (re)engineer decisions for improvement (i.e., decision intelligence) will be critical for any disruption ready and resilient organization.ii
Pyramid Strengthens Commitment to VA and Other Government Agencies
The Pyramid Decision Intelligence Platform is currently used by the Veterans Health Administration, America’s largest integrated health care system, providing care at 1,298 heath care facilities including 171 medical centers and 1,113 outpatient sites throughout the country. The VA provides comprehensive healthcare services to 9 million veterans each year. The Pyramid Decision Intelligence Platform is used by more than 41,000 clinical, medical and administrative staff to identify patterns and execution gaps across the system, ensuring US military veterans receive more personalized and enhanced care to improve the services they offer to veterans and their families.
Accurate and highly contextualized decisions are gaining more importance as government agencies are challenged with unprecedented complexities and uncertainty, backlogs of work and economic disruption, and ongoing labor shortages.
With the Pyramid Platform, government agencies are well positioned to build back better with data-accelerated decisions that improve the ability to deliver critical services for American citizens. Healthcare providers can share information more easily to improve care, transportation agencies can better predict potential delays and solve issues before they happen, supply chains can be managed in real time, and organizations can lower the skills barrier by automating the complex steps required for a data-driven approach.
Decision Intelligence is the Next Big Data Analytics Innovation
The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.
The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
Quotes
Joe Fritsch, Director of Federal Business Practice, Pyramid Analytics: “Pyramid’s Federal Business Practice is the first of many strategic growth initiatives we are launching to expand our partner ecosystem, including federal systems integrators and value-added federal resellers. As Pyramid expands its offerings and further establishes its position as a leading provider of augmented analytics, we are committed to helping U.S. federal civilian, defense, and intelligence agencies expand and optimize their use of data-informed decision intelligence at scale.”
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for everyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. The Pyramid Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.
Pyramid Analytics has regional headquarters in global innovation and business centers including New York City (Pyramid Analytics USA, Inc.), London, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include Jerusalem Venture Partners (JVP), Sequoia Capital and Viola Growth. Learn more at Pyramid Analytics.
____________
i Budget of the U.S. Government Fiscal Year 2023
ii Gartner, 4 Key Actions to Amplify Digital Gains and Resilience in Government, May 20, 2022
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005740/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
